The important role of systemic inflammation in the pathogenesis of both IBD and PD is emphasized by the fact that an early exposure to anti-inflammatory anti-TNF therapy among IBD patients was associated with substantially reduced subsequent PD incidence [99]. The gene discussed is TNF; the disease is inflammatory bowel disease.